Related Experiment Video

Updated: May 12, 2026

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

Regulation of snoRNAs in cancer: close encounters with interferon

Shreeram C Nallar1, Dhananjaya V Kalvakolanu

  • 1Department of Microbiology & Immunology, Greenebaum Cancer Center, University of Maryland School of Medicine , Baltimore, MD 21201, USA.

Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research
|April 11, 2013
PubMed

Insights

Interferons (IFNs) use the GRIM-1 protein to suppress cell growth by reducing mature ribosomal RNA (rRNA) levels. Loss of GRIM-1 suggests its role as a tumor suppressor in cancer.

Area of Science:

  • Cellular Biology
  • Molecular Biology
  • Cancer Research

Background:

  • Interferons (IFNs) are cytokines that regulate crucial cellular processes including growth and survival.
  • Ribosome biogenesis, particularly rRNA maturation, is guided by small nucleolar RNAs (snoRNAs) within ribonucleoprotein particles (snoRNPs).
  • Dysregulation of cellular processes and small RNAs is implicated in cancer development.

Purpose of the Study:

  • To describe a novel interferon-induced pathway that suppresses cell growth by affecting rRNA levels.
  • To elucidate the role of the newly identified GRIM-1 (SHQ1) protein in this pathway.
  • To explore the potential tumor suppressor function of GRIM-1 and the broader implications of small regulatory RNAs in cell growth and cancer.

Main Methods:

  • Genetic screening to identify growth-suppressive genes induced by retinoid-IFN.
  • Characterization of the isolated GRIM-1 (SHQ1) protein as an assembly factor for snoRNPs.
  • Analysis of GRIM-1's impact on sno/scaRNP formation and mature rRNA levels.
  • Review of existing literature on snoRNAs, microRNAs, and their roles in cancer.

Main Results:

  • Interferon-inducible GRIM-1 (SHQ1) was identified as a key regulator of snoRNP biogenesis.
  • GRIM-1 inhibits sno/scaRNP formation, leading to reduced mature rRNA levels and subsequent growth suppression.
  • Loss of GRIM-1 is observed in certain cancers, suggesting its function as a tumor suppressor.
  • Small regulatory RNAs, including snoRNAs and their processed microRNA-like molecules, play significant roles in controlling cell growth and translation.

Conclusions:

  • GRIM-1 acts as an interferon-inducible factor that suppresses cell growth by modulating rRNA maturation.
  • The tumor suppressor role of GRIM-1 in cancer warrants further investigation.
  • Small regulatory RNAs represent a critical network influencing cell proliferation and potentially serving as therapeutic targets in oncology.

More Related Videos

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...